check_circleStudy Completed
Dermatitis, Atopic
Bayer Identifier:
Trial_89171
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Efficacy and tolerance of once-daily methylprednisolone aceponate cream in comparison with twice-daily betamethasone valerate in patients with atopic dermatitis
Trial purpose
A multicenter, open, parallel group comparative study comparing the
therapeutic efficacy and tolerance of methylprednisolone aceponate
(MPA) 0.1% cream once-daily and twice-daily application of
betamethasone valerate (BMV) 0.1% cream in the treatment of
patients of both sexes suffering from atopic dermatitis.
therapeutic efficacy and tolerance of methylprednisolone aceponate
(MPA) 0.1% cream once-daily and twice-daily application of
betamethasone valerate (BMV) 0.1% cream in the treatment of
patients of both sexes suffering from atopic dermatitis.
Key Participants Requirements
Sex
AllAge
14 - N/ATrial summary
Enrollment Goal
152Trial Dates
December 1990 - December 1991Phase
Phase 3Could I Receive a placebo
NoProducts
Advantan (Methylprednisolone Aceponate, BAY86-4862)Accepts Healthy Volunteer
NoPrimary Outcome
- Physician's overall assessment of therapeutic effect at the end of the treatment period
Secondary Outcome
- Objective symptoms (erythema, scaling, lichenification, prurigo, rhagades, and excoriation) assessed as severe, mild or absent
- Subjective complaints (itching, burning, pain) assessed as severe, mild or absent
- Overall skin condition of diseased areas (graded as very good, good, moderate or bad)
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
N/ABlinding
N/AAssignment
Parallel AssignmentTrial Arms
2